M
MGB Biopharma
Developing their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds
About MGB Biopharma
MGB Biopharma, a clinical-stage biopharmaceutical company founded in 2010, is focused on developing a new class of anti-infectives to combat antibiotic resistance. The company's intellectual property originates from the University of Strathclyde, where professors Colin Suckling and Iain Hunter designed and synthesized a novel class of anti-infective compounds. MGB Biopharma was established to license this technology and advance its development, particularly for treating drug-resistant infections. The company has secured funding from investors including Archangel Investors, Scottish Investment Bank, Barwell, and TriCapital Investors to support its clinical trials.
The company's primary business is the research and development of a new class of antibiotics based on DNA minor groove binders (MGBs). This technology targets and disrupts the DNA function of disease-causing pathogens. MGB Biopharma's lead candidate is Ibezapolstat (formerly MGB-BP-3), an oral antibiotic specifically developed to treat Clostridioides difficile-associated disease (CDAD), a serious and often life-threatening intestinal infection. The business model centers on progressing its drug candidates through clinical trials to eventually gain regulatory approval and bring them to market, potentially through partnerships with larger pharmaceutical companies. The primary clients are patients and healthcare organizations dealing with difficult-to-treat bacterial infections.
Ibezapolstat represents a first-in-class DNA polymerase IIIC inhibitor, which gives it a mechanism of action distinct from currently used antibiotics. This enzyme is crucial for DNA replication in certain Gram-positive bacteria, including C. difficile, but is absent in human cells and many beneficial gut bacteria. This selective targeting allows Ibezapolstat to eradicate C. difficile while having a minimal effect on the normal gut flora, which is a significant factor in preventing disease recurrence. Clinical trials have demonstrated the drug's potent bactericidal activity, particularly against the most virulent strains of C. difficile. Phase I and II trials have shown Ibezapolstat to be well-tolerated and effective, achieving high initial and sustained cure rates. The drug has received Qualified Infectious Disease Product (QIDP) and Fast Track designation from the U.S. Food and Drug Administration (FDA).
The company's Chief Executive Officer, Dr. Miroslav Ravic, has extensive experience in clinical practice and drug development. With a PhD in Clinical Pharmacology and previous senior roles at major pharmaceutical companies, his expertise is central to guiding the company's transition from preclinical to clinical development. The company, while listed as in liquidation, continues to report progress on its clinical trials.
Source: Dealroom company dataNews
Open roles
MGB Biopharma in the Glasgow ecosystem
The MGB Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Scottish Enterprise Growth Investments
Tricapital
Archangels
Archangel Ventures
Highlands and Islands Enterprise
Syndicate Room
Barwell
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about MGB Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MGB Biopharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

